ArticleAbdominal radiology (New York)2025
Diagnostic performance of apparent diffusion coefficient values in differentiating benign from malignant lesions in prostate PI-RADS v2.1 category 1 "nodules in nodule".
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo explore the associations between the apparent diffusion coefficient (ADC) values of prostate PI-RADS v2.1 category 1 "nodules in nodule" and their pathological characteristics.
methodsWe retrospectively analyzed the prostate images from 226 male patients who underwent biopsy following MRI from January 2019 to December 2024. Two radiologists evaluated the PI-RADS v2.1 categories of identified nodules, measured the ADC values of the prostate nodules in a double-blind manner, and analyzed the associations between these values and the pathological characteristics of the nodules via independent sample t tests or Mann-Whitney U test.
resultsThe ADC values of PI-RADS v2.1 category 1 "nodules in nodule" pathologically confirmed as clinically significant prostate cancer (csPCa) were lower than those of benign prostate hyperplasia (BPH) ((unit in ×10
conclusionIn patients with PI-RADS v2.1 category 1 "nodules in nodule", when the ADC values are less than 0.835 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.